Message #3 From:
Stock News Bot Date: August 8, 2006 03:30:00 AM
MDSM News Medistem Announces Appointment of Accomplished Researcher Dr. Eduardo Glenn, as Director of New Stem Cell Lab in Costa Rica; New ICM Lab Director to Help Lead Pioneering Work Conducted at ICM Facility
SAN JOSE, Costa Rica--(BUSINESS WIRE)--Aug. 8, 2006--Medistem Laboratories, Inc. (OTCBB:MDSM)(FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced that eminent research microbiologist Dr. Eduardo Glenn has been named Laboratory Director for the new research and treatment facility at its affiliate, the Institute for Cellular Medicine (ICM) in San Jose, Costa Rica.
"Dr. Glenn's appointment is a central addition to the team at ICM, and we are confident he will further energize the pioneering work ICM is conducting with Medistem's stem cell technology," said Chris McGuinn, Vice President and COO of Medistem. "His credentials, reputation, leadership and thorough understanding of stem cell research and its applications bolster Medistem's commitment to pushing the important field of stem cell medicine forward."
Dr. Glenn is a specialist in Medical Bacteriology from the School of Microbiology and Chemistry Clinics in Costa Rica. His distinguished career includes the founding of the First Cord Blood Stem Cell Bank in Central America. Dr. Glenn also founded the Suplilab S.A. Laboratory for Food Control and Toxicology in Costa Rica.
"I am excited to be a part of a pioneering field and hope that we at ICM can help enable finding stem cell applications that will better people's lives," said Dr. Glenn, ICM Lab Director.
The Company also recently filed a U.S. patent application for stem cell-based technology to treat lower back disorders by preventing spinal disc degeneration. According to a study by Duke University, back pain disorders and complaints cost the U.S. economy alone more than $90 billion annually. Medistem's novel technology is designed to address these problems through the application of regenerative stem cell-based medicine.
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The Company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the Company believes to be non-controversial sources of stem cells. Medistem common stock is traded on the Frankfurt, Germany, stock exchange under the symbol S2U. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.
